Skip to content

Aquestive Therapeutics

US · AQST #3650 by market cap Listed 2018
3.46 -0.25 -6.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 3.61 -2.56%
After-hours 3.52 +1.73%
5.393.463.462026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AQST?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -30.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 23.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Gross margin 58.3% Better than 73%
Operating margin -159.5% Better than 6%
Net margin -188.1% Better than 5%
Return on equity -3,347.4% Better than 0%
Return on invested capital -107.7% Better than 2%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -25.8% Better than 22%
6-month return -16.0% Better than 31%
12-month return (ex latest month) -30.1% Better than 9%
Distance below 52-week high 48.6% Better than 20%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.1x Better than 74%
Debt to assets 26.5% Better than 46%
Interest coverage -3.9x Better than 18%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 167.3% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.51%
1M -14.57%
3M -23.03%
6M -17.03%
YTD -46.44%
1Y -38.43%
3Y +93.30%
5Y -42.04%

Key statistics

Price & volume

Prev close
3.71
Open
3.62
Day range
3.41 - 3.65
Avg price
3.51
Volume
3.36M
Turnover
11.78M
Amplitude
6.59%
52-week range
2.93 - 6.74

Valuation

P/E
-4.44
P/E (TTM)
-5.32
P/B
-6.15
EPS
-0.78
Net profit
-98.04M
Net assets
-70.76M

Share structure

Market cap
434.88M
Float cap
391.62M
Shares out
125.69M
Float shares
113.19M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-07-25
52-week range 14% of range
2.93 6.74

48.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-6.50M net over the window

Short interest

Shares short
29.32M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Aquestive Therapeutics (AQST)?

Aquestive Therapeutics last traded at 3.46. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Aquestive Therapeutics's market cap?

About 434.88M.

What is the P/E ratio of Aquestive Therapeutics?

The trailing twelve-month P/E is -5.32. The Valuation tab shows it against the stock's own five-year range.

Does Aquestive Therapeutics pay a dividend?

Aquestive Therapeutics does not currently pay a regular dividend.

Is Aquestive Therapeutics a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 9.25, which implies 167.3% upside from the current price. This is not investment advice.

What is Aquestive Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Aquestive Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Aquestive Therapeutics discussion 0 comments

Add a comment